Testing how blood-clotting is managed in hemophilia with inhibitors
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study looks at different ways to help blood clot in people with hemophilia who have developed inhibitors (proteins that stop standard clotting treatments from working). It may help doctors choose the safest, most effective clotting approach for these situations.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your legal guardian) can give informed consent to join the study
- You fit the study’s main group (people with hemophilia who have inhibitors)
- You must be at least 7 years old
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a clotting factor product called PCC (prothrombin complex concentrate) to treat bleeding episodes in people with hemophilia A who have developed inhibitors. It's for those who are 12–65 and have frequent joint bleeds.
This study collects real-world information on how well a personalized clotting-factor plan helps people with hemophilia A get rid of inhibitors. It may help doctors refine treatment for patients who develop antibodies that block factor therapy.
This study tests whether KN057, a new preventive medicine, is safe for males with hemophilia A or B. It aims to help prevent bleeding episodes without causing unwanted blood clots.
This study tests a new medicine called KN057 for people with hemophilia A or B, with or without inhibitors, to see if it helps prevent bleeding. It is for people who still have frequent bleeding episodes despite current treatments.
This study looks at how the body stops bleeding or forms clots in people with bleeding or clotting disorders. It may help researchers understand these conditions better and improve evaluation tests.
This study tests a therapy called ITI (using SCT800 alone or with daratumumab) to help people with hemophilia A who have inhibitor antibodies that reduce bleeding treatments from working. It may be an option if you’re an adolescent or adult with a high inhibitor level and have not already failed this kind of immune “ITI” treatment before.
Hear when a new Hemophilia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.